Mercado global de biossimilares de adalimumabe – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de biossimilares de adalimumabe

De acordo com o GLOBOCAN 2020, haverá 2.281.658 novos casos de cancro e quase 612.390 mortes nos Estados Unidos em 2020. Além disso, os principais participantes do mercado previram o crescimento do mercado durante o período de previsão através de diversas atividades estratégicas, como lançamentos de produtos, fusões e aquisições. Por exemplo, em julho de 2021, a FDA aprovou o SEMGLEE (insulina-glargina-yfgn) da Viatris Inc. (anteriormente Mylan Pharmaceuticals Inc.), um biossimilar do LANTUS (insulina glargina).

A Data Bridge Market Research analisa que o mercado de biossimilares de adalimumabe, que é de 598,30 milhões de dólares em 2022, deverá atingir os 3.431,48 milhões de dólares até 2030, com um CAGR de 24,4% durante o período de previsão de 2023 a 2030. Além dos insights sobre cenários de mercado como o valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análises especializadas aprofundadas, epidemiologia de pacientes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito e segmentação do mercado biossimilar do adalimumabe      

Definição de mercado

Adalimumab, a monoclonal antibody, is used to treat autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, among others. This medication helps to prevent future joint damage and maintain joint function by reducing joint swelling. As the global prevalence of arthritis rises, the market for adalimumab biosimilars is expected to grow during the forecast period.

Adalimumab Biosimilar Market Dynamics

Drivers

• Rise in biologic drugs

Several blockbuster biologic drugs from major pharmaceutical companies, including Truvada, Chantix, Forteo, Ciprodex, Afinitor, and many others, will lose US exclusivity in 2020. Several existing biological drugs, such as Erbitux, Avastin, and Orencia, will have their patents expire in the coming decade, providing an opportunity for many innovator companies as well as generic manufacturers to offer services specifically tailored toward biosimilars. Furthermore, the cost-effective nature of biosimilars, rising acceptance and adoption by various stakeholders, the need for diversification in technology and business models, and the growing prevalence of chronic diseases are expected to drive the global biosimilar market.

Opportunities

• Rising cancer cases

Cancer's growing burden and rising death toll necessitate the need for affordable treatment, boosting the growth of the biosimilar market. According to GLOBOCAN 2020, there will be 2,281,658 new cancer cases and nearly 612,390 deaths in the United States in 2020. Furthermore, key market participants predicted market growth during the forecast period through a variety of strategic activities such as product launches, mergers, and acquisitions. For instance, in July 2021, the FDA approved Viatris Inc.'s (formerly Mylan Pharmaceuticals Inc.) SEMGLEE (insulin-glargine-yfgn), a biosimilar to LANTUS (insulin glargine).

Restraints/Challenges

• High cost

The high cost associated with biosimilars will obstruct the market's growth rate. However, the global adalimumab biosimilar market is hampered by a scarcity of skilled specialists. Furthermore, factors such as high temperature sensitivity, lack of efficacy and safety, and high manufacturing costs associated with generic drugs are expected to limit market growth between 2022 and 2030.

This adalimumab biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adalimumab biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Adalimumab Biosimilar Market Scope

The adalimumab biosimilar market is segmented on the basis of product and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Exemptia
• Adalirel
• Cipleumab
• Others

Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

Adalimumab Biosimilar Market Regional Analysis/Insights

The adalimumab biosimilar market is analyzed and market size insights and trends are provided by country, product and distribution channel as referenced above.

The countries covered in the adalimumab biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the adalimumab biosimilar market due to the proximity of multiple extensive experimentation laboratories.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the province's extensive commercial advancements and growing biotechnology corporations.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Cenário competitivo e análise da quota de mercado biossimilar de adalimumabe

O panorama competitivo do mercado de biossimilares de adalimumabe fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de biossimilares de adalimumabe.

Alguns dos principais players que operam no mercado dos biossimilares de adalimumabe são:

• Alfred E. Tiefenbacher (GmbH & Co. KG) (Alemanha)
• Amgen Inc.
• Boehringer Ingelheim International GmbH (Alemanha)
• Glenmark (Índia)
• Grupo Zydus (Índia)
• Torrent Pharmaceuticals Ltd. (Índia)
• Reliance Life Sciences (Índia)
• Emcure Pharmaceuticals Ltd (Índia)
• Cipla Inc. (Índia)
• Hetero (Índia)
• AET BioTech (Alemanha)
• Coherus Biosciences (EUA)
• Fujifilm Kyowa Kirin Biologics Co. (Japão)
• Momenta Pharmaceuticals (EUA)
• Oncobiológicos (EUA)
• (EUA)
• Samsung Bioepsis (Coreia do Sul)
• Sandoz International GmbH (Suíça)

SKU-53260